Abingdon Health plc (LSE:ABDX), a specialist in the development and manufacture of lateral flow diagnostics, has highlighted the UK commercial launch of LVOne, described as the first rapid blood test designed to identify stroke at the point of care. The test was developed by customer UpFront Diagnostics and is now being introduced through the London Ambulance Service.
As the contract development and manufacturing organisation (CDMO) partner on the project, Abingdon Health was responsible for feasibility studies, manufacturing scale-up, validation processes, and routine production of LVOne’s dual-biomarker assays. The initial deployment phase will see approximately 280 ambulances equipped with the test as part of a six-month pilot programme in London. The company said the rollout demonstrates its ability to support complex lateral flow diagnostic projects from early-stage development through to commercial production.
Abingdon operates manufacturing facilities in York and Doncaster in the UK, alongside operations in Madison, Wisconsin, and also provides regulatory consulting and analytical testing services through its subsidiaries. These capabilities are aimed at helping in vitro diagnostic and medical device companies achieve regulatory approvals and market access across major international territories.
The company’s outlook continues to be affected by weak financial quality, including ongoing losses, declining gross margins, and negative operating cash flow, despite recording strong revenue growth. Technical indicators remain supportive, with the shares trading above key moving averages and showing a positive MACD trend, although a high RSI reading points to the possibility of near-term overbought conditions. Valuation metrics remain constrained by negative earnings and the absence of a dividend yield.
More About Abingdon Health PLC
Abingdon Health plc is a UK-based med-tech contract services provider specialising in rapid diagnostic testing and regulatory support services for customers worldwide. Its CDMO operations focus on the development and manufacture of lateral flow assays across sectors including infectious disease, clinical diagnostics, animal health, and environmental testing, supported by in-house analytical testing and regulatory consulting expertise in both the UK and the United States.
Leave a Reply